HC Wainwright Forecasts PolyPid’s Q2 Earnings (NASDAQ:PYPD)

PolyPid Ltd. (NASDAQ:PYPD) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings estimates for PolyPid in a note issued to investors on Tuesday, July 21st. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings per share of ($0.36) for the quarter, up from their previous forecast of ($0.38). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.34) per share. HC Wainwright also issued estimates for PolyPid’s Q3 2026 earnings at ($0.40) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($0.84) EPS, FY2028 earnings at ($0.40) EPS, FY2029 earnings at $0.80 EPS and FY2030 earnings at $1.64 EPS.

PolyPid (NASDAQ:PYPD) last posted its earnings results on Wednesday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.12.

Several other equities analysts also recently commented on PYPD. Craig Hallum set a $12.00 price target on shares of PolyPid in a report on Wednesday. Weiss Ratings upgraded PolyPid from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 23rd. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.33.

PolyPid Stock Performance

NASDAQ PYPD opened at $4.00 on Thursday. PolyPid has a fifty-two week low of $3.06 and a fifty-two week high of $5.73. The company has a market cap of $76.32 million, a P/E ratio of -2.09 and a beta of 1.40. The business’s 50 day moving average price is $4.85 and its 200-day moving average price is $4.58.

Hedge Funds Weigh In On PolyPid

A number of large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets raised its stake in shares of PolyPid by 56.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock worth $32,000 after acquiring an additional 3,500 shares in the last quarter. HighTower Advisors LLC acquired a new stake in PolyPid in the 4th quarter worth approximately $44,000. Jane Street Group LLC purchased a new stake in PolyPid during the 4th quarter worth approximately $66,000. Renaissance Technologies LLC purchased a new stake in PolyPid during the 1st quarter worth approximately $81,000. Finally, XTX Topco Ltd increased its stake in PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company’s stock valued at $142,000 after purchasing an additional 10,888 shares in the last quarter. 26.47% of the stock is currently owned by institutional investors.

Trending Headlines about PolyPid

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: PolyPid announced an exclusive partnership with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada for preventing surgical site infections, a deal that could bring in more than $320 million in upfront, milestone, and royalty-related potential. Article Title
• Positive Sentiment: Reuters also reported the Azurity agreement, reinforcing the view that the partnership could meaningfully expand PolyPid’s commercial reach and reduce execution risk for its lead asset. Article Title
• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $13 price target, and slightly raised its Q2 2026 and Q4 2026 EPS estimates, which may be helping sentiment around the stock. Article Title
• Neutral Sentiment: HC Wainwright trimmed some longer-term earnings forecasts for FY2027 through FY2030, suggesting the path to profitability remains uncertain even after the new deal.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.